Most cases of FCS — around 80% — are attributed to mutations (changes) of the LPL gene. Your LPL gene contains the instructions for making an enzyme called lipoprotein lipase (LPL), which your ...
Another European gene therapy company, Amsterdam Molecular Therapeutics (AMT) of Amsterdam, has filed a Marketing Authorization Application with EMEA for its lipoprotein lipase (LPL) deficiency ...
The "Hypertriglyceridemia - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The "Hypertriglyceridemia - Pipeline Insight, 2025" report provides ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback